Acasti Pharma (NASDAQ:ACST – Get Free Report) released its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.10, reports.
Acasti Pharma Price Performance
NASDAQ:ACST opened at $2.18 on Thursday. The stock’s fifty day moving average is $2.35 and its two-hundred day moving average is $2.62. Acasti Pharma has a 52 week low of $1.72 and a 52 week high of $5.05. The stock has a market capitalization of $16.24 million, a price-to-earnings ratio of -0.40 and a beta of 1.34.
Insiders Place Their Bets
In related news, Director Vimal Kavuru acquired 676,371 shares of the business’s stock in a transaction dated Monday, September 25th. The shares were acquired at an average price of $1.85 per share, with a total value of $1,251,286.35. Following the completion of the transaction, the director now owns 1,188,076 shares of the company’s stock, valued at $2,197,940.60. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. 13.51% of the stock is owned by insiders.
Hedge Funds Weigh In On Acasti Pharma
Acasti Pharma Company Profile
Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.
- Five stocks we like better than Acasti Pharma
- Investing in Travel Stocks Benefits
- Buffett’s latest portfolio additions, trims, and cuts in Q3
- When to Sell a Stock for Profit or Loss
- 5 reasons TJX Companies will hit new highs in 2024
- Compound Interest and Why It Matters When Investing
- Game-changing news for Ambarella puts the market in reversal
Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.